Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study

Rissanen, Ina; Ala‐Mursula, Leena; Nerg, Iiro; Korhonen, Marko

doi:10.1007/s10198-021-01271-7

Cited by 10 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MS patients who were willing to participate in the present study were interviewed accordingly. Once the EQ-5D-3L questionnaire was completed, its 5-digit codes were changed into numerical utility by considering the values of Iran determined by Goodarzi et al [ 46 ] using the time trade-off method (TTO).…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Rezaee

Morowvat

Poursadeghfard

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

Introduction Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths of the nerve cells in the brain and spinal cord, which are responsible for communication, are destroyed and cause physical signs and symptoms. According to studies, anti-CD20 monoclonal antibodies have significant results in the treatment of this disease. Thus, the aim of the present study was to determine the cost-effectiveness of rituximab against natalizumab in the patients with RRMS in southern Iran in 2020. Methods This is an economic evaluation including cost-effectiveness analysis in which the Markov model with a lifetime horizon was used. The study sample consisted of 120 patients randomly selected from among those referred to the MS Association and the Special Diseases Unit of Shiraz University of Medical Sciences. In this study, the costs were collected from a societal perspective, and the outcomes were obtained in the form of Quality Adjusted Life Years (QALY) and the mean relapse rate. The TreeAge pro 2020 and Excel 2016 software were used for data analysis. Results The comparative study of rituximab and natalizumab showed that the patients receiving rituximab had lower costs ($ 58,307.93 vs. $ 354,174.85) and more QALYs (7.77 vs. 7.65). In addition, the incidence of relapse by rituximab was lower compared to natalizumab (1.15 vs. 2.57). The probabilistic one-way sensitivity analysis showed the robustness of the results. The scatter plots also showed that rituximab was more cost-effective for the patients in 100% of the simulations for the threshold of < $ 37,641. Discussion and conclusion According to the results of this study, rituximab had higher cost-effectiveness than natalizumab. Therefore, it could be a priority for RRMS patients compared to natalizumab because it reduced treatment costs and increased effectiveness.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Rezaee

Morowvat

Poursadeghfard

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…To discount all monetary values into 2019 euros, the monetary value multiplier from Statistics Finland and the annual data on gross domestic product (GDP) growth in Finland from the World Bank were used. For a more detailed description of the register-based data collection protocol, see Rissanen et al ( 9 ).…”

Section: Methodsmentioning

confidence: 99%

“…Thereafter, these occupation-specific values were adjusted for future labor force participation by considering the proportion of life disability-free (PLDF), national unemployment rate, and the overall decline of work ability in the NFBC1966 population. These adjustments were based on Rissanen et al ( 9 ) and Targoutzidis ( 17 ). The productivity costs (PC) in the HCA model were estimated as follows:…”

Section: Methodsmentioning

confidence: 99%

“…Typically, studies aiming to investigate such costs calculate them using one of two methods—namely, the friction cost approach (FCA) or the human capital approach (HCA) ( 2 ). The FCA demonstrates the employers’ perspective on the costs, whereas the HCA focuses on employees’ perspective related to the same costs ( 9 ). As one example of such research, Ding et al ( 1 ) calculated these costs using FCA.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Individual-Level Productivity Costs of Physical Inactivity

Kari

Nerg

Huikari

et al. 2022

Medicine &Amp; Science in Sports &Amp; Exercise

Self Cite

View full text Add to dashboard Cite

Purpose: This study estimated the long-term individual-level productivity costs of physical inactivity. Methods: The data were drawn from the Northern Finland Birth Cohort 1966, to which the productivity cost variables (sick leaves and disability pensions) from Finnish registries were linked. Individuals (N = 6261) were categorized into physical activity groups based on their level of physical activity, which was measured in three ways: 1) self-reported leisure-time moderate-to vigorous-intensity physical activity (MVPA) at 46 yr old, 2) longitudinal self-reported leisure-time MVPA at 31-46 yr old, and 3) accelerometer-measured overall MVPA at 46 yr old. The human capital approach was applied to calculate the observed costs (years 2012-2020) and the expected costs (years 2012-2031). Results: The results showed that the average individual-level productivity costs were higher among physically inactive compared with the costs among physically active. The results were consistent regardless of the measurement type of physical activity or the period used. On average, the observed long-term productivity costs among physically inactive individuals were €1900 higher based on self-reported MVPA, €1800 higher based on longitudinal MVPA, and €4300 higher based on accelerometer-measured MVPA compared with the corresponding productivity costs among physically active individuals. The corresponding difference in the expected costs was €2800, €1200, and €8700, respectively. Conclusions: The results provide evidence that productivity costs differ according to an individual's level of physical activity. Therefore, investments in physical activity may decrease not only the direct healthcare costs but also the indirect productivity costs paid by the employee, the employer, and the government.

show abstract

“…Most studies on the loss of earnings due to illness have been limited by their use of observational data and short time periods [ 6 , 10 ]. To improve the accuracy of the lifetime survival extrapolation of an index cohort, external data from a reference population that matches in terms of age, sex, and calendar year can be used [ 11 – 13 ].…”

Section: Introductionmentioning

confidence: 99%

Estimation of lifetime productivity loss from patients with chronic diseases: methods and empirical evidence of end-stage kidney disease from Taiwan

Wang,

Hwang,

Huang

et al. 2024

Health Econ Rev

View full text Add to dashboard Cite

Objective Studies that examine the broad allocation of resources, regardless of who bears the costs, should ideally estimate costs from a societal perspective. We have successfully integrated survival rates, employment ratios, and earnings to address the significant challenge of evaluating societal value through productivity assessments of patients with end-stage kidney disease (ESKD) in Taiwan. Methods Using a theoretical framework, we interconnected two nationwide databases: the Taiwan National Health Insurance (NHI) and the Taiwan Mortality Registry from 2000 to 2017. Due to the statutory retirement age of 65, we collected data on all patients (83,358) aged 25–64 years diagnosed with ESKD and undergoing maintenance dialysis. We estimated the lifetime survival function through a rolling extrapolation algorithm, which was then combined with the monthly employment ratio and wages to calculate the lifetime employment duration and productivity up to the legal retirement age of ESKD patients. These were compared with sex-, age-, and calendar year-matched referents to determine the loss of employment duration and productivity of ESKD patients. Results ESKD patients experienced a loss of approximately 25–56% in lifetime employment duration and a larger loss of about 32–66% in lifetime productivity after adjustments for different age, sex, and calendar year. The annual productivity loss per male (female) ESKD patient relative to that of the age-and calendar year-matched referent ranges from 75.5% to 82.1% (82.3% to 90.3%). During the periods when they are able to work (over the on-the-job duration) male ESKD patients lose between 34 and 56% of their income, and female ESKD patients lose between 39 and 68% of their income, compared to the age-and calendar year-matched referents. The loss of lifetime productivity is a combination of reduced lifetime employment duration, functional disability, absenteeism, and presenteeism at the workplace. The loss related to presenteeism is implied by the reduced wages. Conclusions In addition to the loss of employment duration, we have empirically demonstrated the lifetime loss of productivity in patients with ESKD, also indicating the “presenteeism” resulted from inability to perform their job with full capacity over long-term periods.

show abstract

Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study

Cited by 10 publications

References 42 publications

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

The Individual-Level Productivity Costs of Physical Inactivity

Estimation of lifetime productivity loss from patients with chronic diseases: methods and empirical evidence of end-stage kidney disease from Taiwan

Contact Info

Product

Resources

About